Last edition
News about "Duchenne muscular dystrophy "
Somite Therapeutics Receives FDA Orphan Drug and RPDD Designations for SMT-M01
Somite Therapeutics' SMT-M01 program leverages the company's proprietary AlphaStem AI platform to develop a novel cell replacement therapy for DMD.
Duchenne Muscular Dystrophy | 17/09/2024 | By Aishwarya | 227
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members